The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC).
Adam Brufsky
No relevant relationships to disclose
Denise Aysel Yardley
No relevant relationships to disclose
Marianne Ulcickas Yood
Consultant or Advisory Role - Genentech (U)
Debu Tripathy
No relevant relationships to disclose
Peter Andrew Kaufman
Research Funding - Roche/Genentech
Musa Mayer
Consultant or Advisory Role - Genentech (U)
Shibao Feng
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Oyewale O. Abidoye
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Hope S. Rugo
Research Funding - Roche/Genentech